세계의 처방약 시장 : 예측(2025-2030년)

The global prescription drug market is estimated to augment at a CAGR of 4.67%, increasing from US$1,268.008 billion in 2025 to US$1,593.019 billion by the end of 2030.

Prescription drugs are more potent in comparison to over-the-counter (OTC) drugs. Hence, their inappropriate use may lead to serious side effects. These medicines are handed over to customers based on doctors' prescriptions. One might have noticed on the doctor's prescription notepads and signs in most pharmacies that the symbol Rx is the symbol for medical prescription. Growing global pharmaceutical spending will have a significant impact on fueling the market growth during the forecast period.

One of the main drivers is the high cost of specialty medicines and the growing use of medical treatments. The prevalence of rare disorders further propels the market during the forecast period. The increasing number of chronic diseases worldwide is further raising the sales of prescription drugs in the forecast period. The growing number of cancer incidences worldwide is also driving the market expansion during the forecast period.

Furthermore, the growing number of elderly individuals worldwide has significantly raised market growth prospects in the forecast period. The developed regions of the world, particularly North America, is projected to hold a significant share in the prescription drug market. On the other hand, the Asia-Pacific region is regarded as one of the fastest-growing, owing to the prevalence of a large population requiring treatment. In addition, significant investments in improving healthcare infrastructure with better health facilities are further providing an opportunity for the market to grow during the forecast period.

Based on type, the market is categorized as generics, orphan drugs, and other prescription drugs. By application, the global prescription drug market is segregated into diabetes, oncology, cardiovascular diseases, autoimmune diseases, and others. The market is segmented by distribution channel into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

Global Prescription Drugs Market Drivers

• Rising incidences of chronic diseases worldwide

It has been observed on a wide scale that there is a significant rise in the global chronic disease burden. One of the major reasons includes growing urbanization and the adoption of unhealthy living conditions. Additionally, the growing geriatric population worldwide is contributing to the rise of age-associated diseases, further augmenting chronic disease growth and fueling the market growth in the forecast period. Diseases such as Alzheimer's disease, cardiovascular disease, obesity, and diabetes are some chronic diseases. For instance, according to Alzheimer's Disease International (ADI), there were over 55 million people worldwide who are living with dementia as of 2020. The number will almost double in 20 years, reaching 78 million in 2030 and 139 million in 2050. Much of the increase will be in developing countries.

The rising incidences of cancer are further providing an impetus, fueling the market growth in the forecast period. For instance, according to the National Library of Medicine, the estimated incidence of cancer cases in 2022 was 14,61,427 in India. With the crude rate, it was 100.4 cases per 1,00,000 population. In India, one in nine people develops cancer in their lifetime. In males and females, lung and breast cancers are most often found. Lymphoid leukemia (among boys: 29.2% and girls: 24.2%) was the most prevalent childhood (0-14 years) cancer site in India. The incidence of cancer cases is estimated to increase by 12.8 percent in 2025 compared to 2020.

The growing prevalence of cardiovascular diseases is further contributing to the sales of prescription drugs, fueling the market growth in the forecast period. As per the CDC, cardiovascular diseases, comprising disorders of the heart and blood vessels, are ranked as the number one cause of death and disability globally. The major risk factors for this disease include high blood pressure or hypertension, which are attributed to causing a predicted 10 million deaths globally every year.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Global Prescription Drugs market is segmented and analyzed as follows:

By Type

• Generics
• Orphan Drugs
• Others

By Application

• Diabetics
• Oncology
• Cardiovascular Diseases
• Autoimmune Diseases
• Others

By Distribution Channel

• Hospital Pharmacy
• Drug Stores & Retail Pharmacy
• Online Pharmacy

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• UK
• Germany
• France
• Others
• Middle East and Africa
• UAE
• Israel
• Saudi Arabia
• Others
• Asia Pacific
• Japan
• China
• India
• Australia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. Analyst View

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Supplier
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. The Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY TYPE

• 5.1. Introduction
• 5.2. Generics
• 5.3. Orphan Drugs
• 5.4. Others

6. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY APPLICATION

• 6.1. Introduction
• 6.2. Diabetes
• 6.3. Oncology
• 6.4. Cardiovascular Diseases
• 6.5. Autoimmune Diseases
• 6.6. Others

7. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Drug Stores & Retail Pharmacy
• 7.4. Online Pharmacy

8. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. UK
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Others
• 8.5. Middle East and Africa
  • 8.5.1. United Arab Emirates
  • 8.5.2. Israel
  • 8.5.3. Saudi Arabia
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Novartis AG
• 10.2. Pfizer Inc.
• 10.3. Sanofi
• 10.4. Johnson & Johnson Services, Inc.
• 10.5. Merck & Co., Inc.
• 10.6. AbbVie Inc.
• 10.7. GlaxoSmithKline plc.
• 10.8. AstraZeneca
• 10.9. Bristol-Myers Squibb Company
• 10.10. Amgen Inc.
• 10.11. Teva Pharmaceutical Industries Ltd.
• 10.12. Novo Nordisk A/S
• 10.13. Bayer AG
• 10.14. Gilead Sciences, Inc
• 10.15. Eli Lilly and Company
• 10.16. Allergan
• 10.17. Takeda Pharmaceutical Company Limited
• 10.18. Boehringer Ingelheim International GmbH